SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Steven J. Hoffman, Karen So, Assessing 15 Proposals for Promoting Innovation and Access to Medicines Globally, Annals of Global Health, 2014, 80, 6, 432

    CrossRef

  2. 2
    Luisa Ronga, Marco Del Favero, Anita Cohen, Claire Soum, Patrice Le Pape, Solène Savrimoutou, Noël Pinaud, Catherine Mullié, Sylvie Daulouede, Philippe Vincendeau, Natacha Farvacques, Patrice Agnamey, Fabrice Pagniez, Sébastien Hutter, Nadine Azas, Pascal Sonnet, Jean Guillon, Design, synthesis and biological evaluation of novel 4-alkapolyenylpyrrolo[1,2-a]quinoxalines as antileishmanial agents – Part III, European Journal of Medicinal Chemistry, 2014, 81, 378

    CrossRef

  3. 3
    Tim K. Mackey, Bryan A. Liang, Raphael Cuomo, Ryan Hafen, Kimberly C. Brouwer, Daniel E. Lee, Emerging and Reemerging Neglected Tropical Diseases: a Review of Key Characteristics, Risk Factors, and the Policy and Innovation Environment, Clinical Microbiology Reviews, 2014, 27, 4, 949

    CrossRef

  4. 4
    Yves Jackson, Niamh Stephenson, Neglected tropical disease and emerging infectious disease: An analysis of the history, promise and constraints of two worldviews, Global Public Health, 2014, 9, 9, 995

    CrossRef

  5. 5
    D.E. Keyler, I. Gawarammana, J.M. Gutiérrez, K.H. Sellahewa, K. McWhorter, R. Malleappah, Antivenom for snakebite envenoming in Sri Lanka: The need for geographically specific antivenom and improved efficacy, Toxicon, 2013, 69, 90

    CrossRef

  6. 6
    Banchiwossen Bekele, Legesse Adane, Yinebeb Tariku, Asrat Hailu, Evaluation of antileishmanial activities of triglycerides isolated from roots of Moringa stenopetala, Medicinal Chemistry Research, 2013, 22, 10, 4592

    CrossRef

  7. 7
    Irene Ruberto, Balazs Szoor, Rachel Clark, Keith R. Matthews, Investigating Mammalian Tyrosine Phosphatase Inhibitors as Potential ‘Piggyback’ Leads to Target Trypanosoma brucei Transmission, Chemical Biology & Drug Design, 2013, 81, 2
  8. 8
    Frank Mueller-Langer, Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?, Health Economics, Policy and Law, 2013, 8, 02, 185

    CrossRef

  9. 9
    John A. Butera, Phenotypic Screening as a Strategic Component of Drug Discovery Programs Targeting Novel Antiparasitic and Antimycobacterial Agents: An Editorial, Journal of Medicinal Chemistry, 2013, 56, 20, 7715

    CrossRef

  10. 10
    Matthew Herder, When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada, Accountability in Research, 2013, 20, 4, 227

    CrossRef

  11. 11
    Maria Hedlund, Epigenetic Responsibility, Medicine Studies, 2012, 3, 3, 171

    CrossRef

  12. 12
    Geoffrey M Lairumbi, Michael Parker, Raymond Fitzpatrick, Michael C English, Forms of benefit sharing in global health research undertaken in resource poor settings: a qualitative study of stakeholders' views in Kenya, Philosophy, Ethics, and Humanities in Medicine, 2012, 7, 1, 7

    CrossRef

  13. 13
    Tim K. Mackey, Bryan A. Liang, Global health policy coordination to address neglected tropical diseases, Tropical Medicine & International Health, 2012, 17, 9
  14. 14
    Varun Gauri, Jorn Sonderholm, Global poverty: four normative positions, Journal of Global Ethics, 2012, 8, 2-3, 193

    CrossRef

  15. 15
    Catherine M. Montgomery, Protocols and participatory democracy in a ‘North–South’ product development partnership, Sociology of Health & Illness, 2012, 34, 7
  16. 16
    Tim K. Mackey, Bryan A. Liang, Threats from emerging and re-emerging neglected tropical diseases (NTDs), Infection Ecology & Epidemiology, 2012, 2, 0

    CrossRef

  17. 17
    J. Sonderholm, Advance Monopoly Commitment?, Public Health Ethics, 2011, 4, 3, 297

    CrossRef

  18. 18
    Angela Fehr, Petra Thürmann, Oliver Razum, Expert Delphi survey on research and development into drugs for neglected diseases, BMC Health Services Research, 2011, 11, 1, 312

    CrossRef

  19. 19
    Nisha Jain Garg, Global Health: Neglected Diseases and Access to Medicines, Infectious Disease Clinics of North America, 2011, 25, 3, 639

    CrossRef

  20. 20
    Assena Stoimenova, Manoela Manova, Alexandra Savova, Bistra Angelovska, Guenka Petrova, Reimbursed Orphan Medicines in Bulgaria and the Share of Biotechnology-Derived Products, Biotechnology & Biotechnological Equipment, 2011, 25, 2, 2418

    CrossRef

  21. 21
    Andrew Harmer, Understanding change in global health policy: Ideas, discourse and networks, Global Public Health, 2011, 6, 7, 703

    CrossRef

  22. 22
    S Christensen, Ib Bygbjerg, Bioactive Compounds from Natural Sources, Second Edition, 2011,

    CrossRef

  23. 23
    J. Sonderholm, A Reform Proposal in Need of Reform: A Critique of Thomas Pogge's Proposal for How to Incentivize Research and Development of Essential Drugs, Public Health Ethics, 2010, 3, 2, 167

    CrossRef

  24. 24
    Simone S. Grecco, Juliana Q. Reimão, Andre G. Tempone, Patricia Sartorelli, Paulete Romoff, Marcelo J. P. Ferreira, Oriana A. Fávero, Joao H. G. Lago, Isolation of an antileishmanial and antitrypanosomal flavanone from the leaves of Baccharis retusa DC. (Asteraceae), Parasitology Research, 2010, 106, 5, 1245

    CrossRef

  25. 25
    M. Boelaert, F. Meheus, J. Robays, P. Lutumba, Socio–economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis, Annals of Tropical Medicine & Parasitology, 2010, 104, 7, 535

    CrossRef

  26. 26
    Julio A. Urbina, Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches, Acta Tropica, 2010, 115, 1-2, 55

    CrossRef

  27. 27
    Patrícia Sartorelli, Camila Salomone Carvalho, Juliana Quero Reimão, Marcelo José Pena Ferreira, André Gustavo Tempone, Antiparasitic activity of biochanin A, an isolated isoflavone from fruits of Cassia fistula (Leguminosae), Parasitology Research, 2009, 104, 2, 311

    CrossRef

  28. 28
    Joanna E Lowell, Christopher D Earl, Leveraging biotech's drug discovery expertise for neglected diseases, Nature Biotechnology, 2009, 27, 4, 323

    CrossRef

  29. 29
    Shailesh Kumar, Nishi Shakya, Suman Gupta, Jayanta Sarkar, Devi Prasad Sahu, Synthesis and biological evaluation of novel 4-(hetero) aryl-2-piperazino quinazolines as anti-leishmanial and anti-proliferative agents, Bioorganic & Medicinal Chemistry Letters, 2009, 19, 9, 2542

    CrossRef

  30. You have free access to this content30
    M. Boelaert, F. Meheus, A. Sanchez, S. P. Singh, V. Vanlerberghe, A. Picado, B. Meessen, S. Sundar, The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India, Tropical Medicine & International Health, 2009, 14, 6
  31. 31
    André Gustavo Tempone, Daniel Carvalho Pimenta, Ivo Lebrun, Patrícia Sartorelli, Noemi N. Taniwaki, Heitor Franco de Andrade, Marta Maria Antoniazzi, Carlos Jared, Antileishmanial and antitrypanosomal activity of bufadienolides isolated from the toad Rhinella jimi parotoid macrogland secretion, Toxicon, 2008, 52, 1, 13

    CrossRef

  32. 32
    Jens Van Roey, Myriam Haxaire, The Need to Reform Current Drug Registration Processes to Improve Access to Essential Medicines in Developing Countries, Pharmaceutical Medicine, 2008, 22, 4, 207

    CrossRef

  33. 33
    Nafsika Georgopapadakou, Discontinued drugs in 2005: anti-infectives, Expert Opinion on Investigational Drugs, 2007, 16, 1, 1

    CrossRef

  34. 34
    Patrícia Sartorelli, Samanta P. Andrade, Márcia S. C. Melhem, Frederico O. Prado, André G. Tempone, Isolation of antileishmanial sterol from the fruits of Cassia fistula using bioguided fractionation, Phytotherapy Research, 2007, 21, 7
  35. 35
    Thomas A. Kursar, Catherina C. Caballero-George, Todd L. Capson, Luis Cubilla-Rios, William H. Gerwick, Maria V. Heller, Alicia Ibañez, Roger G. Linington, Kerry L. McPhail, Eduardo Ortega-Barría, Luz I. Romero, P. D. Coley, Linking bioprospecting with sustainable development and conservation: the Panama case, Biodiversity and Conservation, 2007, 16, 10, 2789

    CrossRef

  36. 36
    Paul N Newton, Michael D Green, Facundo M Fernández, Nicholas PJ Day, Nicholas J White, Counterfeit anti-infective drugs, The Lancet Infectious Diseases, 2006, 6, 9, 602

    CrossRef

  37. 37
    Angela Fehr, Petra Thürmann, Oliver Razum, Editorial: Drug development for neglected diseases: a public health challenge, Tropical Medicine & International Health, 2006, 11, 9
  38. 38
    Samantha Byrne, Paul Davey, Kirsti McFarlane, John O'Brien, Craig Templeton, Patent rights or patent wrongs? The case of patent rights on AIDS drugs, Business Ethics: A European Review, 2006, 15, 3
  39. 39
    Solomon Nwaka, Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 20

    CrossRef

  40. 40
    Thomas W. Pogge, HUMAN RIGHTS AND GLOBAL HEALTH: A RESEARCH PROGRAM, Metaphilosophy, 2005, 36, 1-2
  41. 41
    Thomas Pogge, Severe Poverty as a Violation of Negative Duties, Ethics & International Affairs, 2005, 19, 1
  42. 42
    Tim Hubbard, James Love, A New Trade Framework for Global Healthcare R&D, PLoS Biology, 2004, 2, 2, e52

    CrossRef

  43. 43
    Richard Reithinger, Khoksar Aadil, Samad Hami, Jan Kolaczinski, Cutaneous Leishmaniasis, Northern Afghanistan, Emerging Infectious Diseases, 2004, 10, 5, 966

    CrossRef

  44. 44
    Giuseppe Remuzzi, Arrigo Schieppati, Jean-Pierre Boissel, Silvio Garattini, Richard Horton, Independent clinical research in Europe, The Lancet, 2004, 364, 9446, 1723

    CrossRef

  45. 45
    Solomon Nwaka, Lise Riopel, David Ubben, J.Carl Craft, Medicines for Malaria Venture new developments in antimalarials, Travel Medicine and Infectious Disease, 2004, 2, 3-4, 161

    CrossRef

  46. 46
    Richard T. Mahoney, Ariel Pablos-Mendez, S. Ramachandran, The introduction of new vaccines into developing countries, Vaccine, 2004, 22, 5-6, 786

    CrossRef

  47. 47
    Richard Reithinger, Mohammad Mohsen, Khoksar Aadil, Majeed Sidiqi, Panna Erasmus, Paul G. Coleman, Anthroponotic Cutaneous Leishmaniasis, Kabul, Afghanistan, Emerging Infectious Diseases, 2003, 9, 6, 727

    CrossRef

  48. 48
    H.Ulrich Göringer, Matthias Homann, Mihaela Lorger, In vitro selection of high-affinity nucleic acid ligands to parasite target molecules, International Journal for Parasitology, 2003, 33, 12, 1309

    CrossRef

  49. 49
    Solomon Nwaka, Robert G. Ridley, Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships, Nature Reviews Drug Discovery, 2003, 2, 11, 919

    CrossRef

  50. 50
    A.G. Habib, Tetanus complicating snakebite in northern Nigeria:, Acta Tropica, 2003, 85, 1, 87

    CrossRef

  51. 51
    Alimuddin Zumla, Drugs for neglected diseases, The Lancet Infectious Diseases, 2002, 2, 7, 393

    CrossRef

  52. 52
    M. Boelaert, F. Matthys, M. Henkens, U. D'Alessandro, European Union’s research policy: a moving target?, Tropical Medicine & International Health, 2001, 6, 11
  53. 53
    Balázs Szöör, Keith R. Matthews, Protein Phosphatases in Trypanosome Growth and Development,
  54. 54
    Curtis R. Chong, Repurposing Drugs for Tropical Diseases: Case Studies and Open-Source Screening Initiatives,